Close Menu

Ambry

In the wake of the US Supreme Court's decision to strike down Myriad Genetics' patents on isolated BRCA1 and BRCA2 gene sequences, GeneDx this week become the latest laboratory to launch sequencing-based tests for inherited cancer that include those genes.

This article has been updated from a previous version that stated incorrectly that Gene by Gene has performed 1 million BRCA tests globally.

After being sued by Myriad Genetics for allegedly infringing its patents on BRCA1 and BRCA2 gene mutation testing, Ambry Genetics pushed back this week with its own countersuit accusing Myriad of antitrust violations.

NEW YORK (GenomeWeb News) – In response to Myriad Genetics' patent infringement lawsuit against Ambry Genetics, the Aliso Viejo, Calif.-based testing firm took its own legal action today by countersuing Myriad for antitrust violations.

Ever since the Supreme Court struck down Myriad Genetics' patent claims on isolated BRCA1 and BRCA2 gene sequences, industry observers have breathlessly speculated whether the company would take legal action against labs challenging its decades-long reign over the BRCA genetic te

This article has been updated to include a response from Ambry.

Ardy Arianpour is now senior vice president of business development at Ambry Genetics. He previously served as vice president of business development at the company. Arianpour joined Ambry in 2009 after holding several positions at Cogenics.

Following the US Supreme Court's decision two weeks ago to strike down Myriad Genetics' central patent claims to the BRCA1 and BRCA2 genes, several US genetic testing laboratories have been gearing up to snatch a piece of the BRCA testing market in this country, previously Myriad

Jonathan Rothberg has resigned from his position as CEO of Life Technologies' Ion Torrent business, according to a filing with the US Securities and Exchange Commission.

Pages

A small, early-stage trial of a combination therapy for brain cancer reports favorable responses in two patients, according to the Guardian.

Nature News writes that viral genomic surveillance in the US faces systemic issues.

President Joe Biden is seeking an increase in federal spending, including higher budgets for the National Institutes of Health and Centers for Disease Control and Prevention.

In PLOS this week: sex-stratified genome-wide association study of chronic pain, sequencing data from Indigenous Mexican groups, and more.